DEF 14C: TRxADE Health to Become Scienture Holdings Following Merger with Scienture, Inc.

TRxADE Health, Inc. will change its name to Scienture Holdings, Inc. after completing its merger with Scienture, Inc., a specialty pharmaceutical company.

Summary

• TRxADE Health, Inc. (TRxADE) has merged with Scienture, Inc., with TRxADE changing its name to Scienture Holdings, Inc.
• The merger was executed through a series of transactions, including mergers of subsidiaries of TRxADE with and into Scienture.
• As consideration for the merger, Scienture's stockholders received 291,555 shares of TRxADE common stock (representing 19.99% of outstanding shares) and 6,826,713 shares of Series X Preferred Stock, each convertible into one share of TRxADE common stock.
• The merger agreement was approved by TRxADE's board and a majority of its stockholders via written consent.
• The company intends to file a resale registration statement with the SEC upon request from the Initiating Holders.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the merger itself is a positive step for TRxADE, the financial challenges faced by Scienture and the potential for dilution temper the overall outlook.

Positives

• The board believes that the merger will create value for the stockholders of the combined organization and an opportunity for TRxADE's stockholders to participate in the potential growth of the combined company.
• The combined company would be able to take advantage of the potential benefits resulting from the combination of the technological platforms and infrastructure of both the Company and Scienture.

Negatives

• The issuance of securities in connection with the Preferred Stock Conversion will have a dilutive effect on TRxADE's existing stockholders.
• The Preferred Stock Conversion could also dilute the voting power of a person seeking control of the Company, thereby deterring or rendering more difficult a merger, tender offer, proxy contest or an extraordinary corporate transaction opposed by the Company.
• In August 2024, Kesin demanded immediate payment of $1.285 million under the Kesin Termination Agreement, which Scienture disputes.

Risks

• Scienture does not have any product candidates approved for sale and has not generated any revenue from product sales.
• Scienture's expectations regarding its research and development programs are subject to risks, including the risk that Scienture's financial condition and results of operations for fiscal year 2024 and beyond may be materially and adversely affected by delays and failures in the completion of clinical development of its product candidates, which could increase its costs or delay or limit our ability to generate revenues.
• There can be no assurance that an amicable resolution will be obtained with Kesin. If Kesin brings a legal action, Scienture will vigorously defend it.

Future Outlook

Scienture expects its operating expenses to increase substantially in future years in connection with ongoing activities, particularly as it continues the research and development of, continue or initiate clinical trials of, and seek marketing approval for any current and future product candidates.

Industry Context

The announcement reflects a trend of consolidation in the pharmaceutical industry, where companies seek to expand their product pipelines and market reach through mergers and acquisitions.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• However, the focus on developing treatments for CNS and CVS diseases aligns with areas of significant unmet medical need and ongoing research and development efforts in the pharmaceutical industry.
• Comparable companies in the specialty pharmaceutical space include companies like Amarin Corporation (cardiovascular), Biohaven Pharmaceutical Holding Company (neurology), and Acadia Pharmaceuticals (CNS disorders).

Legal Proceedings

• In August 2024, Kesin demanded immediate payment of the full amount under the Kesin Termination Agreement, which Scienture disputes.

Stakeholder Impact

• Existing TRxADE stockholders will experience dilution due to the issuance of new shares.
• TRxADE will change its name to Scienture Holdings, Inc.

Next Steps

• Prepare and file a resale registration statement with the SEC.
• File the certificate of amendment to the Companys Second Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware effecting the Name Change.
• Notify Nasdaq of the Name Change.

Key Dates

Keywords

merger, Scienture, TRxADE, preferred stock, common stock, conversion, pharmaceutical, holdings, agreement